dated in multiethnic Asian CKD populations outside of the original derivation populations, and the question exists whether GFR estimation is improved using cystatin C-based equations so that adjustments for ethnicity are not required. In an earlier study, we determined that GFR estimation with the CKD-EPI equation is more accurate than the MDRD equation in a multiethnic Asian CKD population for a wider GFR range (9 ) . In this study, we compared the accuracy of the CKD-EPI equation to several serum cystatin C-based equations and evaluated derived ethnicity coefficients in a multiethnic Asian population with chronic kidney disease.
METHODS
This was a parallel substudy of the Asian Kidney Disease Study approved by the institution review board. Briefly, we recruited patients with CKD presenting to the outpatient nephrology clinics in the National University Hospital, Singapore. The inclusion criteria were (a) age Ͼ21 years, (b) serum creatinine with an estimated or measured GFR (mGFR) (MDRD, , or creatinine clearance) of 10 -90 mL/min, (c) stable CKD defined as 2 serum creatinines measured Ͼ60 days apart of Ͻ20% difference, and (d) the definition of CKD followed the clinical practice guidelines (11, 12 ) . Patients were excluded if they had any of the following: (a) inability to consent, (b) physical conditions that render phlebotomy for blood samples difficult, (c) inability to collect urine samples successfully, (d) acute kidney function deterioration, amputation, edema, pleural effusion or ascites, skeletal muscle atrophy, or any condition that potentially interferes with the accuracy of the measurement of GFR. The patients were recruited consecutively with stratified sampling by 4 ethnic groups (Chinese, Malay, Indian, and other) and further by sex. Participants performed self-directed 24-h urine collections and underwent GFR measurement the next day, with blood and spot urine samples collected at the same time. All samples were processed within 4 h and stored at Ϫ80°C. On completion of the recruitment of patients, stored serum samples were assayed for serum cystatin C concentration.
LABORATORY TESTS
Patients were allowed a light, no-protein breakfast and underwent a GFR determination (British Nuclear Medicine Society guidelines) by 3-sample plasma clearance of 99m Tc-DTPA by use of an intravenous bolus of Technescan diethylene triamine pentaacetic acid (DTPA) (Mallinckrodt Medical BV) (13 ) . GFR was calculated by the slope-intercept method, normalized to body surface area, with the result corrected using the Brochner-Mortenson equation (14 ) . Body surface area was calculated using the du Bois equation (15 ) . The measured GFR is comparable to that obtained by urinary clearance of inulin (16 -18 ) . Serum creatinine was measured by an enzymatic method and calibrated with materials traceable to standardized creatinine (Siemens Advia), and serum cystatin C (cysC) was measured by particle-enhanced immunonephelometry on the BN Prospec platform (Dade Behring) in batches in 2009. All assays were performed in a central clinical laboratory accredited by the College of American Pathologists. The mean CV for the 2-year period of 2009 -2010 for creatinine was 1.55% for both level 1 and 2 controls (1.27 and 5.92 mg/dL, respectively); range 0.80%-3.22%. The accuracy program for creatinine (CAP LN24) had a range of Ϫ4.6%-3.9% across 4 programs (goal for total error 10%). The CV for cystatin C results was 5.2%-6.2%. Cystatin C is not a clinical service test and we did not subscribe to an evaluation program, hence we were unable to determine any bias. We standardized serum cystatin C (ScysC) using adjustment equation 2: ScysC ϭ 1.12 ϫ cysC (19 ) .
GFR ESTIMATION
We estimated GFR using the CKD-EPI equation (2 ) 2 . This may result in inadequate time for preparing for end-stage kidney failure at the lower GFR, and conversely, extremely premature preparations and excessively frequent follow-ups at higher GFR. Therefore, to truly determine if new estimating equations are improvements, we also assessed them using the tighter P15 criterion. We transformed measured GFR and serum creatinine to natural logarithms. To obtain ethnicity coefficients for the equations based on serum cystatin C, we forced all other coefficients to be the same as in the original equations and used our data to calibrate the coefficients for ethnicity (8 ) . We modeled the ratio between mGFR and eGFR against the proposed ethnicity variable with the intercept forced to zero: 
Results
There were 232 participants with a mean (SD) age of 58. 4 (12.8) Chinese and highest in Malays (P Ͻ 0.001). The standardized serum cystatin C concentration was lowest in Chinese (P ϭ 0.05) but was not significantly different between Malay and Indian patients. The distributions of serum creatinine and standardized serum cystatin C with measured GFR are shown in Fig. 1 and Supplemental Fig.  1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol58/issue2.
eGFR VS mGFR
Compared to the CKD-EPI equation, the serum cystatin-based equations eGFR2 and eGFR3 had greater bias overall ( Table 2 ). The RMSE and precision of equations eGFR2 and eGFR3 were not better (NS) but improved with eGFR3. P30 accuracy was improved in all equations, and P15 accuracy increased by 7.3%.
PERFORMANCE OF CHINESE-SPECIFIC EQUATIONS
In the Chinese subpopulation, the Chinese-specific equations developed by Ma et al. (7 ) had greater bias than the CKD-EPI equation (19 ) and the serum cystatin C-based equations (Table 3) . Nonetheless, the performance of the cystatin-based equations improved with the addition of demographic variables and had the best performance in combination with serum creatinine. Compared to the CKD-EPI equation, the cystatin-based equations did not consistently show improvements in all of the accuracy performance parameters; however, P15 and P30 were higher using eGFR3.
PERFORMANCE IN NON-CHINESE POPULATIONS
In the non-Chinese groups, bias was greater using the US cystatin C-based equations (eGFR1, eGFR2, and eGFR3) compared to CKD-EPI (Table 4) . Again, performance improved with the addition of demographic variables, with the best performance obtained when combined with serum creatinine. Whereas RMSE was not better than with the CKD-EPI equation, precision was marginally improved with equation eGFR3 in both Malays and Indians and others.
DERIVED ETHNICITY COEFFICIENTS
For all patients, we derived "Asian" coefficients for equations eGFR2 and eGFR3 of 1.077 (95% CI 1.046 -1.109, P Ͻ 0.001), and 1.061 (1.032-1.090, P Ͻ 0.001), Multiple Biomarkers to Estimate GFR in Asians respectively. We also derived Chinese coefficients of 1.064 (1.019 -1.110, P ϭ 0.006) and 1.082 (1.037-1.127, P Ͻ 0.001) for equations eGFR2 and eGFR3, respectively. We derived Malay coefficients of 1.123 (1.057-1.190, P Ͻ 0.001) and 1.081 (1.026 -1.135, P ϭ 0.004) for equations eGFR2 and eGFR3. We derived "Indians and others" coefficients of 1.043 (0.995-1.091, P ϭ 0.008) and 1.009 (0.955-1.062, p ϭ NS) for equations eGFR2 and eGFR3.
Discussion
Our study shows that the serum cystatin C-based GFRestimating equations for CKD patients that incorporate demographic variables and/or standardized serum creatinine perform as well as the CKD-EPI equation. The equations having serum cystatin C alone (eGFR1 and eGFR2) are not better than with the CKD-EPI equation. The best performance is obtained using the combination biomarker equation (eGFR3) with demographic variables. The P30 accuracy performance parameter recommended by the NKF KDOQI guidelines is similar between eGFR3 (88.4%) and the CKD-EPI equation (82.8%) and is close to that achieved by other validation studies of the MDRD study equations (12, 20 ) . The P15 accuracy is increased by 7.3% in eGFR3 compared to the CKD-EPI equation. This improvement in accuracy of GFR estimation and, consequently, correctness of CKD staging, while requiring only a spot serum test, is attractive for both clinical care and research.
The derived ethnicity coefficients for eGFR3 equation range from 1.009 to 1.082. We note that the generated ethnicity coefficients for all ethnic groups were all Ͼ1. Taken together with the persistence of a lower (but still Ͼ1) coefficient for African-Americans for equations eGFR2 and eGFR3 (1.06 and 1.11, respectively), our results suggest that cystatin C adjusts estimated GFR downward (8 ) . We previously argued that unless there is a con- a Data are mean (SD) unless noted otherwise. b Chinese Ͻ Malay, P Ͻ 0.001; Chinese Ͻ Indian and others, P ϭ 0.046; Malay vs Indian and others, P ϭ 0.21. c Chinese Ͻ Malay, P Ͻ 0.001; Chinese Ͻ Indian and others, P ϭ 0.012, Malay Ͼ Indian and others, P ϭ 0.046. d Chinese Ͻ Malay, P ϭ 0.0296; Malay vs Indian and others, P ϭ 0.0588; Chinese vs Indian and others, P ϭ 0.937.
sistent, Ͼ10% bias between measured and estimated GFR, it would be difficult to attribute derived ethnicity coefficients to true ethnic differences in GFR (9 ) . This is because the bias may be a result of differences arising from the constituting derivation population, biomarker assay calibration, GFR measurement method, and physiologic variability. A study population with more high-GFR patients can be expected to have greater variability and differences in measured GFR. Therefore, ethnicity coefficients may arise due to chance, particularly if the study population is small. Serum creatinine calibration is an important source of bias and may be the cause of the ethnicity coefficient (9, 21, 22 ) . Physiologic variability and different GFR measurement techniques may result in up to 20% differences (13, 17, 23 ) . We previously showed that varying the protocol for the calculation of GFR measurements by the slope-intercept method reduced a derived Chinese coefficient for the MDRD study equation by 2% (9 ) . Moreover, with the exception of the Indian and others group, equation eGFR3 yielded ethnicity coefficients for the Malay and Chinese groups that were marginally higher than 1 within their 95% CIs, further supporting the idea that ethnicity adjustment is not required for the combination biomarker equation in multiethnic Asian populations. It is unlikely that a large, representative, economical study will be performed to develop "true" ethnicity coefficients. Like other studies, our ethnicity coefficients were derived mathematically (9, 21, 24 ) . The proliferation of such coefficients will not be practical or practicable in many cosmopolitan cities and countries. Our study is the first to suggest that a multiple biomarker approach to GFR-estimating equations may obviate ethnicity coefficients because the adjustment quanta are small. Therefore, in the absence of external validation, we do not recommend the use of our derived ethnicity coefficients. Our study results do suggest that equation eGFR3, however, can be used without considering ethnicity coefficients in Asians with CKD both within and outside the US. In the Chinese subgroup, the Chinese-specific equations also showed improved performance when demographic variables were added (7 ). The bias and other accuracy parameters, however, were poorer than with the serum cystatin C-based equations derived from the US population. In fact, the straight application of the combination biomarkers equation (eGFR3) performed very well, yielding GFR estimates with similar or better precision and accuracy (P15 and P30). One possible reason is that our laboratory had the advantage of calibrating our serum creatinine assays to standardized serum creatinine and reducing assay variability with an enzymatic method, thereby obviating one source of bias. Although there is concern that serum cystatin C is a potential source of bias or measurement error, the risk is lower since we used the same assay type as in the previous study and calibrated the nephelometer with manufacturer-provided calibrators (7, 8, 25 ) . Nonetheless, recent studies suggest that the Siemens assay (Dade Behring) has changed over time (26, 27 ) . We note that the CKD-EPI cystatin C study assayed serum cystatin C from frozen samples in 2005-2006 (8 ) . Therefore, bias and any derived coefficients in this study may be caused by this elapsed time. Moreover, our cystatin C assays also were performed before the availability (June 2010) of an international cystatin C reference material (ERM-DA471/IFCC). Fortunately, the timing of our study assays (2009) permits us to mathematically adjust our serum cystatin C results to standardized cystatin C (19) .
Our data also suggests that in multiethnic CKD populations, it would be possible to increase precision and percentage accuracy to within 15% and 30% of the mea- sured GFR by using the equation for a combination of biomarkers (eGFR3) without considering ethnicity coefficients. If assay costs are not an impediment, the Ͼ7% increase in the proportion of patients achieving this margin of accuracy would improve the accuracy of screening programs and epidemiological studies of CKD, particularly for GFR in the range of 60 -90 mL/min/1.73m 2 . Why should the addition of serum cystatin C to serum creatinine improve GFR estimation, especially in a multiethnic Asian population? Prior studies have alluded to the fact that serum creatinine-based equations underestimate and serum cystatin C-based equations overestimate GFR, and the average yield the best estimate (6, 8, 28 ) . This may be related to factors responsible for the generation of these biomarkers. Serum creatinine generation reflects the amount of lean muscle mass (4 ) . Body mass index influences serum cystatin C generation (29 -31 ) . We suspect that the degree of ethnic and environmental influences on fat and muscle proportion is rendered less important once we average the GFR estimates using a combination of these 2 markers. It would be helpful to have a future study evaluate the contribution of fat mass to cystatin C concentrations between different ethnic populations.
One major limitation of our study is the use of a different GFR measurement technique from the previous study (8 ) . Bias may be attributed to the use of wholeplasma clearance of 99m Tc-DTPA, which can overestimate or underestimate GFR measured by urinary clearance of iothalamate (17, 23 ) . Our method of calculating GFR may also result in a small difference despite using a technique similar to that used by the Beijing investigators (7 ). Our nephelometer was different, although cystatin C was calibrated with manufacturer-provided materials and used the same type of assay described in previous studies (7, 8 ) . Whereas we had a representative population of CKD patients including some with diabetes, we did not have kidney transplant patients and healthy individuals. Therefore, the application of the cystatin C-based equations in other populations cannot be defined (8, 28) . But we note that the cystatin C equations considered in this study were derived from CKD patients and excluded healthy people. As in other Asian studies, the various ethnicity coefficients were derived mathematically because we did not have comparator group of patients of European descent.
In summary, our study shows that a combined serum cystatin C and standardized creatinine GFR-estimating equation performs similarly to the CKD-EPI equation. In multiethnic Asian CKD populations, it is reasonable to use this equation without adjustments for ethnicity. 
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